Analyst Price Target is $23.00
▲ +842.62% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Palisade Bio in the last 3 months. The average price target is $23.00, with a high forecast of $38.00 and a low forecast of $8.00. The average price target represents a 842.62% upside from the last price of $2.44.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Palisade Bio. This rating has held steady since October 2023, when it changed from a Hold consensus rating.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
Read More
